Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: A multicenter phase II study

Kyung Hee Lee, Min Kyoung Kim, Yeul Hong Kim, Baek Yeol Ryoo, Ho Yeong Lim, Hong Suk Song, Hoon Kyo Kim, Myung Ah Lee, Seock Ah Im, Heung Moon Chang, Jae Yong Cho, Dae Young Zang, Bong Seog Kim, Jun Suk Kim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: Gemcitabine is the only drug approved for single-agent therapy in advanced pancreatic carcinoma (APC). Gemcitabine-based combination chemotherapy has not yet shown promising results. Methods: This multicenter phase II study enrolled previously untreated patients with locally advanced and/or metastatic pancreatic adenocarcinoma. Patients received 1,000 mg/m2 gemcitabine, 100-min infusion, day 1 and 100 mg/m2 oxaliplatin, 2-h infusion, day 2; q2w. The primary end point was response rate (RR). Results: Thirteen study centers enrolled 48 eligible patients of which 44 were evaluable. The RR, median overall survival, and median time to progression were 18.2%, 9.4 and 5.6 months, respectively. Sixteen patients (36.4%) experienced clinical benefit. The global quality of life scores improved by 11.71. Grade 3/4 peripheral sensory neuropathy was noted (2.1%), while the most common hematologic toxicity was anemia (grade 3/4, 6.3%). Conclusions: Gemcitabine and oxaliplatin combination chemotherapy showed a promising activity in APC patients and was well tolerated.

Original languageEnglish
Pages (from-to)317-325
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Volume64
Issue number2
DOIs
Publication statusPublished - 2009 Jul 1

Fingerprint

oxaliplatin
gemcitabine
Pancreatic Neoplasms
Chemotherapy
Combination Drug Therapy
Therapeutics
Toxicity
Peripheral Nervous System Diseases
Anemia
Adenocarcinoma
Quality of Life

Keywords

  • Advanced pancreatic cancer
  • Combination chemotherapy
  • Gemcitabine
  • GEMOX
  • Oxaliplatin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer : A multicenter phase II study. / Lee, Kyung Hee; Kim, Min Kyoung; Kim, Yeul Hong; Ryoo, Baek Yeol; Lim, Ho Yeong; Song, Hong Suk; Kim, Hoon Kyo; Lee, Myung Ah; Im, Seock Ah; Chang, Heung Moon; Cho, Jae Yong; Zang, Dae Young; Kim, Bong Seog; Kim, Jun Suk.

In: Cancer Chemotherapy and Pharmacology, Vol. 64, No. 2, 01.07.2009, p. 317-325.

Research output: Contribution to journalArticle

Lee, KH, Kim, MK, Kim, YH, Ryoo, BY, Lim, HY, Song, HS, Kim, HK, Lee, MA, Im, SA, Chang, HM, Cho, JY, Zang, DY, Kim, BS & Kim, JS 2009, 'Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: A multicenter phase II study', Cancer Chemotherapy and Pharmacology, vol. 64, no. 2, pp. 317-325. https://doi.org/10.1007/s00280-008-0873-9
Lee, Kyung Hee ; Kim, Min Kyoung ; Kim, Yeul Hong ; Ryoo, Baek Yeol ; Lim, Ho Yeong ; Song, Hong Suk ; Kim, Hoon Kyo ; Lee, Myung Ah ; Im, Seock Ah ; Chang, Heung Moon ; Cho, Jae Yong ; Zang, Dae Young ; Kim, Bong Seog ; Kim, Jun Suk. / Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer : A multicenter phase II study. In: Cancer Chemotherapy and Pharmacology. 2009 ; Vol. 64, No. 2. pp. 317-325.
@article{7a775f80b6874f089e51e58e9009460b,
title = "Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: A multicenter phase II study",
abstract = "Purpose: Gemcitabine is the only drug approved for single-agent therapy in advanced pancreatic carcinoma (APC). Gemcitabine-based combination chemotherapy has not yet shown promising results. Methods: This multicenter phase II study enrolled previously untreated patients with locally advanced and/or metastatic pancreatic adenocarcinoma. Patients received 1,000 mg/m2 gemcitabine, 100-min infusion, day 1 and 100 mg/m2 oxaliplatin, 2-h infusion, day 2; q2w. The primary end point was response rate (RR). Results: Thirteen study centers enrolled 48 eligible patients of which 44 were evaluable. The RR, median overall survival, and median time to progression were 18.2{\%}, 9.4 and 5.6 months, respectively. Sixteen patients (36.4{\%}) experienced clinical benefit. The global quality of life scores improved by 11.71. Grade 3/4 peripheral sensory neuropathy was noted (2.1{\%}), while the most common hematologic toxicity was anemia (grade 3/4, 6.3{\%}). Conclusions: Gemcitabine and oxaliplatin combination chemotherapy showed a promising activity in APC patients and was well tolerated.",
keywords = "Advanced pancreatic cancer, Combination chemotherapy, Gemcitabine, GEMOX, Oxaliplatin",
author = "Lee, {Kyung Hee} and Kim, {Min Kyoung} and Kim, {Yeul Hong} and Ryoo, {Baek Yeol} and Lim, {Ho Yeong} and Song, {Hong Suk} and Kim, {Hoon Kyo} and Lee, {Myung Ah} and Im, {Seock Ah} and Chang, {Heung Moon} and Cho, {Jae Yong} and Zang, {Dae Young} and Kim, {Bong Seog} and Kim, {Jun Suk}",
year = "2009",
month = "7",
day = "1",
doi = "10.1007/s00280-008-0873-9",
language = "English",
volume = "64",
pages = "317--325",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer

T2 - A multicenter phase II study

AU - Lee, Kyung Hee

AU - Kim, Min Kyoung

AU - Kim, Yeul Hong

AU - Ryoo, Baek Yeol

AU - Lim, Ho Yeong

AU - Song, Hong Suk

AU - Kim, Hoon Kyo

AU - Lee, Myung Ah

AU - Im, Seock Ah

AU - Chang, Heung Moon

AU - Cho, Jae Yong

AU - Zang, Dae Young

AU - Kim, Bong Seog

AU - Kim, Jun Suk

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Purpose: Gemcitabine is the only drug approved for single-agent therapy in advanced pancreatic carcinoma (APC). Gemcitabine-based combination chemotherapy has not yet shown promising results. Methods: This multicenter phase II study enrolled previously untreated patients with locally advanced and/or metastatic pancreatic adenocarcinoma. Patients received 1,000 mg/m2 gemcitabine, 100-min infusion, day 1 and 100 mg/m2 oxaliplatin, 2-h infusion, day 2; q2w. The primary end point was response rate (RR). Results: Thirteen study centers enrolled 48 eligible patients of which 44 were evaluable. The RR, median overall survival, and median time to progression were 18.2%, 9.4 and 5.6 months, respectively. Sixteen patients (36.4%) experienced clinical benefit. The global quality of life scores improved by 11.71. Grade 3/4 peripheral sensory neuropathy was noted (2.1%), while the most common hematologic toxicity was anemia (grade 3/4, 6.3%). Conclusions: Gemcitabine and oxaliplatin combination chemotherapy showed a promising activity in APC patients and was well tolerated.

AB - Purpose: Gemcitabine is the only drug approved for single-agent therapy in advanced pancreatic carcinoma (APC). Gemcitabine-based combination chemotherapy has not yet shown promising results. Methods: This multicenter phase II study enrolled previously untreated patients with locally advanced and/or metastatic pancreatic adenocarcinoma. Patients received 1,000 mg/m2 gemcitabine, 100-min infusion, day 1 and 100 mg/m2 oxaliplatin, 2-h infusion, day 2; q2w. The primary end point was response rate (RR). Results: Thirteen study centers enrolled 48 eligible patients of which 44 were evaluable. The RR, median overall survival, and median time to progression were 18.2%, 9.4 and 5.6 months, respectively. Sixteen patients (36.4%) experienced clinical benefit. The global quality of life scores improved by 11.71. Grade 3/4 peripheral sensory neuropathy was noted (2.1%), while the most common hematologic toxicity was anemia (grade 3/4, 6.3%). Conclusions: Gemcitabine and oxaliplatin combination chemotherapy showed a promising activity in APC patients and was well tolerated.

KW - Advanced pancreatic cancer

KW - Combination chemotherapy

KW - Gemcitabine

KW - GEMOX

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=67349175594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349175594&partnerID=8YFLogxK

U2 - 10.1007/s00280-008-0873-9

DO - 10.1007/s00280-008-0873-9

M3 - Article

C2 - 19034448

AN - SCOPUS:67349175594

VL - 64

SP - 317

EP - 325

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -